{
  "analysis_mode": "HISTORICAL_ONLY",
  "report_version": "5.0",
  "symbol": "STX.L",
  "generated_at": "2026-02-06T23:46:09.663381+00:00",
  "comprehensive_apex": {
    "score": 30,
    "rating": "LOW QUALITY",
    "color": "#ef4444",
    "calculation": "(60\u00d725% + 40\u00d720% + 48.3\u00d730% + 47\u00d725%) \u00d7 0.6 = 30",
    "components": {
      "setup": {
        "score": 60,
        "weight": 0.25
      },
      "trust": {
        "score": 40,
        "weight": 0.2
      },
      "panic": {
        "score": 48.3,
        "weight": 0.3
      },
      "compression": {
        "score": 47,
        "weight": 0.25
      }
    },
    "timing": {
      "regime": "CROWDED",
      "multiplier": 0.6
    }
  },
  "top_card": {
    "ticker": "STX.L",
    "company_name": "Shield Therapeutics plc",
    "sector": "Healthcare",
    "market_cap_gbp": 102527717,
    "days_active": 571,
    "apex_score_100": 60,
    "confidence_score_100": 40,
    "panic_score_100": 48.3,
    "cc_score_100": 47,
    "ai_final_score_25": 11,
    "ai_strength": "MODERATE",
    "timing_regime": "CROWDED",
    "action": "SELL/TAKE_PROFITS",
    "thesis_one_liner": "SELL/TAKE_PROFITS - CROWDED timing with 60/100 opportunity score",
    "overall_score_100": 49
  },
  "enrichment": {
    "company_info": {
      "name": "Shield Therapeutics plc",
      "sector": "Healthcare",
      "industry": "Drug Manufacturers - Specialty & Generic",
      "exchange": "LSE",
      "market": "AIM",
      "currency": "GBP",
      "risk_tier": "High Risk",
      "current_market_cap": 102527717,
      "current_close_price": 9.6
    },
    "basics": {
      "ticker": "STX.L",
      "current_price": 9.6,
      "ath": 184.8142,
      "atl": 1.063,
      "ath_date": "2020-01-08",
      "atl_date": "2024-04-25",
      "week_52_high": 12.5,
      "week_52_low": 2.1,
      "week_52_high_date": "2025-12-04",
      "week_52_low_date": "2025-04-17",
      "drawdown_from_ath_pct": 94.81,
      "data_start": "2020-01-02",
      "data_end": "2026-02-06",
      "total_bars": 1541
    },
    "latest_signal": {
      "date": "2024-07-15",
      "scan_date": "2026-01-26",
      "signal_type": "CRASH ZONE BOTTOM",
      "signal_color": "YELLOW",
      "price": 1.6,
      "drawdown_pct": 87.55,
      "ai_score": 9.0,
      "rsi": 18.2,
      "cycle_position": 0.1818,
      "holding_period_days": 571,
      "current_pnl_pct": 500.0,
      "rally_state": "rallying",
      "distance_from_high_pct": -17.11,
      "Rally_Count": 1,
      "days_since_last_high": 10,
      "last_high_date": "2026-01-16",
      "lock_in_reached": true,
      "lock_in_date": "2026-01-16",
      "best_rally_pct": 662.5
    },
    "best_historical_signal": {
      "signal_date": "2024-04-25",
      "signal_type": "EXTREME CRASH BOTTOM",
      "signal_color": "ORANGE",
      "entry_price": 1.225,
      "peak_price": 12.5,
      "peak_date": "2025-12-04",
      "rally_pct": 920.41,
      "days_to_peak": 588,
      "ai_score": 13.0
    },
    "all_historical_signals": [
      {
        "signal_id": "STX.L_2022-06-30",
        "signal_date": "2022-06-30",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.2857,
        "current_price": 10.1125,
        "current_return_pct": 38.8,
        "best_rally_pct": 75.33,
        "best_rally_date": "2022-09-07",
        "rally_state": "pulling_back",
        "Rally_Count": 9,
        "distance_from_high_pct": -20.84,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1306,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-07-01",
        "signal_date": "2022-07-01",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.5285,
        "current_price": 10.1125,
        "current_return_pct": 34.32,
        "best_rally_pct": 69.68,
        "best_rally_date": "2022-09-07",
        "rally_state": "pulling_back",
        "Rally_Count": 8,
        "distance_from_high_pct": -20.84,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1305,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-07-04",
        "signal_date": "2022-07-04",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.5085,
        "current_price": 10.1125,
        "current_return_pct": 55.37,
        "best_rally_pct": 96.27,
        "best_rally_date": "2022-09-07",
        "rally_state": "pulling_back",
        "Rally_Count": 9,
        "distance_from_high_pct": -20.84,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1302,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-07-05",
        "signal_date": "2022-07-05",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.3628,
        "current_price": 10.1125,
        "current_return_pct": 58.93,
        "best_rally_pct": 100.76,
        "best_rally_date": "2022-09-07",
        "rally_state": "pulling_back",
        "Rally_Count": 6,
        "distance_from_high_pct": -20.84,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1301,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-07-08",
        "signal_date": "2022-07-08",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.2414,
        "current_price": 10.1125,
        "current_return_pct": 62.02,
        "best_rally_pct": 104.67,
        "best_rally_date": "2022-09-07",
        "rally_state": "pulling_back",
        "Rally_Count": 5,
        "distance_from_high_pct": -20.84,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1298,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-10-27",
        "signal_date": "2022-10-27",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.5285,
        "current_price": 10.1125,
        "current_return_pct": 34.32,
        "best_rally_pct": 66.04,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 7,
        "distance_from_high_pct": -19.1,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1187,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-10-28",
        "signal_date": "2022-10-28",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.2857,
        "current_price": 10.1125,
        "current_return_pct": 38.8,
        "best_rally_pct": 71.57,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 8,
        "distance_from_high_pct": -19.1,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1186,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-10-31",
        "signal_date": "2022-10-31",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 7.5285,
        "current_price": 10.1125,
        "current_return_pct": 34.32,
        "best_rally_pct": 66.04,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 7,
        "distance_from_high_pct": -19.1,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1183,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-12-13",
        "signal_date": "2022-12-13",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.8,
        "current_price": 10.1125,
        "current_return_pct": 48.71,
        "best_rally_pct": 83.82,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 9,
        "distance_from_high_pct": -19.1,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1140,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-12-14",
        "signal_date": "2022-12-14",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.9214,
        "current_price": 10.1125,
        "current_return_pct": 46.1,
        "best_rally_pct": 80.6,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 8,
        "distance_from_high_pct": -19.1,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1139,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2022-12-19",
        "signal_date": "2022-12-19",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 6.9,
        "current_price": 10.1125,
        "current_return_pct": 46.56,
        "best_rally_pct": 81.16,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 8,
        "distance_from_high_pct": -19.1,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1134,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2023-01-05",
        "signal_date": "2023-01-05",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 6.6,
        "current_price": 10.1125,
        "current_return_pct": 53.22,
        "best_rally_pct": 89.39,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 8,
        "distance_from_high_pct": -19.1,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1117,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2023-01-06",
        "signal_date": "2023-01-06",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 6.5,
        "current_price": 10.1125,
        "current_return_pct": 55.58,
        "best_rally_pct": 92.31,
        "best_rally_date": "2023-09-25",
        "rally_state": "rallying",
        "Rally_Count": 8,
        "distance_from_high_pct": -19.1,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 1116,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-02-27",
        "signal_date": "2024-02-27",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 2.42,
        "current_price": 10.1125,
        "current_return_pct": 317.87,
        "best_rally_pct": 404.13,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 4,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 699,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-02",
        "signal_date": "2024-04-02",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 2.0,
        "current_price": 10.1125,
        "current_return_pct": 405.63,
        "best_rally_pct": 510.0,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 3,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 664,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-03",
        "signal_date": "2024-04-03",
        "signal_type": "ENHANCED DEEP CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 1.9,
        "current_price": 10.1125,
        "current_return_pct": 432.24,
        "best_rally_pct": 542.11,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 3,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 663,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-04",
        "signal_date": "2024-04-04",
        "signal_type": "ENHANCED DEEP CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 1.775,
        "current_price": 10.1125,
        "current_return_pct": 469.72,
        "best_rally_pct": 587.32,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 3,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 662,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-05",
        "signal_date": "2024-04-05",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.7,
        "current_price": 10.1125,
        "current_return_pct": 494.85,
        "best_rally_pct": 617.65,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 2,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 661,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-08",
        "signal_date": "2024-04-08",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.7,
        "current_price": 10.1125,
        "current_return_pct": 494.85,
        "best_rally_pct": 617.65,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 2,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 658,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-09",
        "signal_date": "2024-04-09",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.65,
        "current_price": 10.1125,
        "current_return_pct": 512.88,
        "best_rally_pct": 639.39,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 2,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 657,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-12",
        "signal_date": "2024-04-12",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.525,
        "current_price": 10.1125,
        "current_return_pct": 563.11,
        "best_rally_pct": 700.0,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 2,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 654,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-16",
        "signal_date": "2024-04-16",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.525,
        "current_price": 10.1125,
        "current_return_pct": 563.11,
        "best_rally_pct": 700.0,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 2,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 650,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-17",
        "signal_date": "2024-04-17",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.48,
        "current_price": 10.1125,
        "current_return_pct": 583.28,
        "best_rally_pct": 724.32,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 2,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 649,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-25",
        "signal_date": "2024-04-25",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 1.225,
        "current_price": 10.1125,
        "current_return_pct": 725.51,
        "best_rally_pct": 895.92,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 1,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 641,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-26",
        "signal_date": "2024-04-26",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.35,
        "current_price": 10.1125,
        "current_return_pct": 649.07,
        "best_rally_pct": 803.7,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 1,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 640,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-29",
        "signal_date": "2024-04-29",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.35,
        "current_price": 10.1125,
        "current_return_pct": 649.07,
        "best_rally_pct": 803.7,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 1,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 637,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-04-30",
        "signal_date": "2024-04-30",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.35,
        "current_price": 10.1125,
        "current_return_pct": 649.07,
        "best_rally_pct": 803.7,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 1,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 636,
        "status": "historical"
      },
      {
        "signal_id": "STX.L_2024-07-15",
        "signal_date": "2024-07-15",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.6,
        "current_price": 10.1125,
        "current_return_pct": 532.03,
        "best_rally_pct": 662.5,
        "best_rally_date": "2026-01-16",
        "rally_state": "rallying",
        "Rally_Count": 1,
        "distance_from_high_pct": -17.11,
        "days_since_last_high": 10,
        "lock_in_reached": true,
        "age_days": 560,
        "status": "historical"
      }
    ],
    "stats": {
      "total_signals": 28,
      "win_rate_pct": 100.0,
      "avg_rally_pct": 411.07,
      "median_rally_pct": 470.76,
      "best_rally_pct": 920.41,
      "worst_rally_pct": 70.68
    },
    "splits": [],
    "split_risk": {
      "split_detected": false,
      "risk_level": "NONE",
      "confidence": "HIGH"
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [
      "EXTREME_DRAWDOWN",
      "FREQUENT_CRASHES"
    ],
    "last_updated": "2026-02-06 20:04:47 UTC",
    "volatility": {
      "atr_normalized": 8.18,
      "stddev_20d": 0.0
    },
    "trends": {
      "intelligence_signal": "UPTREND"
    }
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 60/100 indicates strong opportunity quality",
      "Timing regime: CROWDED",
      "Historical profile: 1 rallies, 662% best run"
    ],
    "main_risk": "Confidence 40/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "STX.L",
      "latest": [
        {
          "title": "Total Voting Rights",
          "date": "30th Jan 2026",
          "announcement_date": "30th Jan 2026",
          "release_time": "7:05 am",
          "source": "RNS",
          "content": "Today 07:05\nRNS Number : 0034R\nShield Therapeutics PLC\n30 January 2026\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nTotal Voting Rights\nLondon, UK, 30 January, 2026:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital consists of\n1,067,997,016\nordinary shares of 1.5p each in issue, each with equal voting rights. No shares are held in treasury.\nThe above figure may also be used by shareholders as the denominator in the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\nhttps://shieldtherapeutics.com/link/P2AzZr\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the leading\n#1 branded prescription oral iron the market today\n(data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, with Kye Pharmaceuticals Inc. for Canada, and with VITAL-NET for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTVRPPUUPGUPQPGB",
          "rns_number": "RNS Number : 0034R"
        },
        {
          "title": "Approval for ACCRUFeR in China expected in Q1 2026",
          "date": "30th Jan 2026",
          "announcement_date": "30th Jan 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "Today 07:00\nRNS Number : 0029R\nShield Therapeutics PLC\n30 January 2026\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\nShield Therapeutics plc\n(\"Shield\" or the \"Company\")\nFiling for marketing authori\nsation\nfor the approval for ACCRUFeR\u00ae in China\nexpected in Q1 2026 and will include the pediatric data\nTerms of the China License Agreement with ASK updated to include a $7.9Mdevelopment milestone to Shield by 31 January 2026\nShield to use the\nASK development milestone payment to settle all payments andterminate the AOP Milestone Monetisation Agreement\nLondon, UK, January 30, 2026:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency announces that its partner in China, Beijing Aosaikang Pharmaceutical Co. Ltd (\"ASK\"), expects to submit the file for marketing authorisation to the China National Medical Products Administration (\"NMPA\") for the approval for ACCRUFeR\u00ae in China in Q1 2026. The Company and ASK have agreed to update various terms of the China License Agreement including a development milestone of $7.9M to Shield by 31 January 2026. Shield will use the ASK development milestone to settle its obligations under the AOP Milestone Monetisation Agreement and terminate the agreement.\nASK plans to include the positive data from Shield's Phase 3 pediatric clinical trial (FORTIS/ST10-01-305) that was used to receive US FDA approval to extend the indication for ACCRUFeR\u00ae in the US to include children 10 years and older with iron deficiency (ID) in its NMPA filing for Marketing Authorisation for ACCRUFeR\u00ae in China. The NMPA filing is anticipated in Q1 2026.\nIn addition to ASK agreeing to pay Shield a development milestone of $7.9M, the Company and ASK have agreed to update various terms of the China License Agreement including a milestone of up to $3M linked to the final price for ACCRUFeR\u00ae in China, and revised royalties of up to 10% based on annual net sales of ACCRUFeR\u00ae. The updated milestones replace the $11.4M milestone which was conditional upon receipt of a subsequently expected marketing approval in China.\nThe Company will use the $7.9M development milestone payment from ASK to settle all its obligations under the terms of the AOP Milestone Monetisation Agreement. The final payment amount to AOP will fully discharge the Company's financial obligations to AOP under that agreement. This payment is significantly below the amount which would have been due to AOP if the full $11.4M marketing approval milestone payment had been received by Shield from ASK.\nSantosh Shanbhag, CFO at Shield, commented:\n\"\nWe are pleased to see the continued progress of our partner ASK towards the planned submission for marketing authorisation of ACCRUFeR\u00ae in China in the first quarter of 2026. We believe that the inclusion of the recently approved US pediatric Phase 3 data strengthens the overall submission package and supports the long\u2011term value of ACCRUFeR\u00ae in this important market. In parallel, the amended terms of the agreement with ASK allows Shield to use the development milestone payment from ASK to fully cover the final payment due to AOP and terminate the AOP Milestone Monetisation Agreement earlier and at lower cost than previously planned. This further simplifies our capital structure and places Shield in a stronger financial position as we continue to execute our commercial strategy.\"\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\nhttps://shieldtherapeutics.com/link/y0z57r\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is America's #1 branded prescription oral iron for ID/IDA (data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. FeRACCRU\u00ae is also commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc. for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCEAFFNAEEKEAA",
          "rns_number": "RNS Number : 0029R"
        },
        {
          "title": "Q4 2025 Trading Update",
          "date": "21st Jan 2026",
          "announcement_date": "21st Jan 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "Today 07:00\nRNS Number : 6821P\nShield Therapeutics PLC\n21 January 2026\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018). Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nQ4 2025 Trading Update\nGenerated positive Cash flow in Q4 2025 with Total Group Revenues of c. $50m for full year 2025\nACCRUFeR\u00ae revenues grew 56% to c. $46m in 2025 with 21% increase in average net selling price to $223and 33% growth in total prescriptions to c.199,000\nCompany expects to deliver an operating profit in 2026\nLondon, UK, 21 January 2026:\nShield Therapeutics plc (LSE: STX),\u00a0a commercial-stage pharmaceutical company\nspecialising in iron deficiency,\nannounces that, in line with the Company's guidance, Shield has achieved positive operating cash flow in Q4 2025 and provides an\nunaudited full year\u00a0trading update for the year ended 31 December 2025 (\"FY25\").\nThis period reflects the transition of the Company to a sustainable enterprise\ndriven by continued ACCRUFeR\u00ae growth in the US and effective cost and working capital management. The Company also announces that it expects to deliver an operating profit in 2026.\nThe Company reported total revenues of c. $50m for FY25 ($32m revenues and other income in FY24) with ACCRUFeR\u00ae revenues growing 56% in the US and contributing $46m ($29m in FY24) through 21% growth in average net selling price to $223 and 33% growth in total prescriptions to c.199,000.\nQ4 2025 Key Business Metrics:\n\u00b7\nACCRUFeR\u00ae net revenues\nof $13.5m ($11.2m Q4 2024).\n\u00b7\nACCRUFeR\u00ae prescriptions\nof c. 61,000 (c. 41,000 in Q4 2024) representing the highest dispenses in any quarter since launch. Consignment-based prescriptions decreased c. 21% (c. 22% in Q4 2024) that were dispensed at a subsidised price to patients and were not yet reimbursed by payors.\n\u00b7\nACCRUFeR\u00ae average net selling price\nof $222\n($237 in Q4 2024) impacted by an increase in covered rebated prescriptions compared to prior quarters.\n\u00b7\nCash and cash equivalents\nof $11.6m as\nof 31 December 2025 (\n$8.6m\nas of 30 September 2025), achieving positive operative cash flow of $1m excluding the receipt of net proceeds of $1.96m from the amended Senior Secured Debt Financing announced in the quarter.\nAnders Lundstrom, Chief Executive Officer, commented\n:\n\"Reaching cash flow positivity is a significant milestone in the Company's history that allows us to continue to grow our business without the need for further external financing. The efforts of the sales teams, together with our strategic marketing initiatives, delivered our strongest year on record for ACCRUFeR\u00ae, achieving new highs in prescription volumes, net selling price, and revenues. ACCRUFeR\u00ae's strong performance in the fourth quarter along with a strengthened balance sheet exiting 2025 gives us the momentum and financial flexibility to achieve our 2026 strategic priorities.\"\nInvestor Presentation\nCEO, Anders Lundstrom, and CFO, Santosh Shanbhag, will be hosting a live online presentation relating to the Q4 2025 Trading Update\nvia the Investor Meet Company platform\nat\u00a02:00 pm\u00a0(GMT) on 22 January 2026.\nThe presentation is open to all existing and potential investors. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 1.00 pm (BST) on 22 January 2026 or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet Shield Therapeutics plc via:\nhttps://www.investormeetcompany.com/shield-therapeutics-plc/register-investor\nInvestors who already follow Shield Therapeutics plc on the Investor Meet Company platform will automatically be invited.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Christopher Golden\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the leading #1 branded prescription oral iron the market today for ID/IDA (data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, with Kye Pharmaceuticals Inc. for Canada, and with VITAL-NET for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTSTURUURNWUAUUR",
          "rns_number": "RNS Number : 6821P"
        },
        {
          "title": "Block listing 6 Monthly Return",
          "date": "2nd Jan 2026",
          "announcement_date": "2nd Jan 2026",
          "release_time": "11:06 am",
          "source": "RNS",
          "content": "2 Jan 2026 11:06\nRNS Number : 4870N\nShield Therapeutics PLC\n02 January 2026\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nBlock Listing 6 Monthly Return\nName of\u00a0applicant:\nSHIELD THERAPEUTICS PLC\nName of scheme:\nShield Therapeutics Retention Share Plan\nPeriod of return:\nFrom:\n01 July 2025\nTo:\n31 December 2025\nBalance of unallotted securities under scheme(s) from previous return:\n39,794\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\nNIL\nLess:\nNumber of\u00a0securities\u00a0issued/allotted under scheme(s) during period (see LR3.5.7G):\nNIL\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n39,794\nName of\u00a0applicant:\nSHIELD THERAPEUTICS PLC\nName of scheme:\nShield Therapeutics plc 2016 Company Share Option Plan\nPeriod of return:\nFrom:\n01 July 2025\nTo:\n31 December 2025\nBalance of unallotted securities under scheme(s) from previous return:\n341,020\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\nNIL\nLess:\nNumber of\u00a0securities\u00a0issued/allotted under scheme(s) during period (see LR3.5.7G):\nNIL\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n341,020\nName of\u00a0applicant:\nSHIELD THERAPEUTICS PLC\nName of scheme:\nThe Shield Therapeutics plc 2016 Long Term Incentive Plan\nPeriod of return:\nFrom:\n01 July 2025\nTo:\n31 December 2025\nBalance of unallotted securities under scheme(s) from previous return:\n24,273\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\nNIL\nLess:\nNumber of\u00a0securities\u00a0issued/allotted under scheme(s) during period (see LR3.5.7G):\nNIL\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n24,273\nName of\u00a0applicant:\nSHIELD THERAPEUTICS PLC\nName of scheme:\nShield Therapeutics Retention and Performance Share Plan\nPeriod of return:\nFrom:\n01 July 2025\nTo:\n31 December 2025\nBalance of unallotted securities under scheme(s) from previous return:\n2,870,838\nPlus:\nThe amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):\n15,000,000\nLess:\nNumber of\u00a0securities\u00a0issued/allotted under scheme(s) during period (see LR3.5.7G):\n6,137,791\nEquals:\nBalance under scheme(s) not yet issued/allotted at end of period:\n11,733,071\nName of contact:\nLucy Huntington-Bailey\nTelephone number of contact:\n+44 (0) 191 511 8500\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nLucy Huntington-Bailey, Company Secretary\n+44 (0) 191 511 8500\ninfo@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Christoper Golden\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the leading #1 branded prescription oral iron the market today (data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. FeRACCRU\u00ae is also commercialised in Canada by Kye Pharmaceuticals Inc. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, and with Medleap Pharma Company Limited, a subsidiary of VITAL-NET Inc. for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nBLREAFFAEESKEFA",
          "rns_number": "RNS Number : 4870N"
        },
        {
          "title": "Total Voting Rights",
          "date": "2nd Jan 2026",
          "announcement_date": "2nd Jan 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "2 Jan 2026 07:00\nRNS Number : 3615N\nShield Therapeutics PLC\n31 December 2025\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\nTotal Voting Rights\nLondon, UK, 31 December, 2025:\nShield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital consists of\n1,067,828,251\nordinary shares of 1.5p each in issue, each with equal voting rights. No shares are held in treasury.\nThe above figure may also be used by shareholders as the denominator in the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.\nFor further information please contact:\nShield Therapeutics plc\nwww.shieldtherapeutics.com\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nStephanie Hicks, Investor Relations\n+44 (0) 191 511 8500\nInvestorrelations@shieldtx.com\nNominated Adviser and Joint Broker\nPeel Hunt LLP\nJames Steel/Christopher Golden\n+44 (0)20 7418 8900\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward\n+44 (0)20 7220 0500\nAbout Iron Deficiency and ACCRUFeR\u00ae/FeRACCRU\u00ae\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR\u00ae has the potential to meet an important unmet medical need for both physicians and patients\nand is now the leading\n#1 branded prescription oral iron the market today\n(data source - IQVIA Xponent PlanTrak).\nACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA.\nThe drug\nhas a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about ACCRUFeR\u00ae/\nFeRACCRU\u00ae\n, including the product label, can be found at:\nwww.accrufer.com\nand\nwww.feraccru.com\n.\nAbout Shield Therapeutics plc\nShield is a commercial stage specialty pharmaceutical company that delivers ACCRUFeR\u00ae/FeRACCRU\u00ae (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia.\nThe Company has launched ACCRUFeR\u00ae in the U.S. with an exclusive, multi-year collaboration agreement with Viatris. Outside of the U.S., the Company has licensed the rights to five specialty pharmaceutical companies. FeRACCRU\u00ae is commercialised in the UK and European Union by Norgine B.V., which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of ACCRUFeR\u00ae/FeRACCRU\u00ae in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea, with Kye Pharmaceuticals Inc. for Canada, and with VITAL-NET for Japan.\nACCRUFeR\u00ae/FeRACCRU\u00ae has patent coverage\nuntil the mid-2030s.\nACCRUFeR\u00ae/FeRACCRU\u00ae are registered trademarks of Shield Therapeutics.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTVRWPGMUPUPAGAG",
          "rns_number": "RNS Number : 3615N"
        }
      ],
      "themes": [
        "drilling",
        "operations",
        "regulatory"
      ]
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 582,
      "sentiment_breakdown": {
        "positive": 0.0,
        "neutral": 100.0,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 0,
      "momentum_score": 0,
      "trend_direction": "flat",
      "intelligence_signal": "UPTREND"
    },
    "volatility": {
      "atr_normalized": 8.18,
      "stddev_20d": 0.0
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    },
    "catalyst_dates": {
      "proxy_date": "2026-01-16"
    }
  },
  "ai_insights": {
    "key_insights": [],
    "hidden_patterns": [],
    "contrarian_signals": [],
    "risk_warnings": [],
    "opportunity_flags": [
      "INFORMATION ASYMMETRY: 53 RNS announcements but only 0 social posts. Market may not have fully digested company developments."
    ],
    "narrative_summary": "STX.L shows 0 key patterns worth attention. Primary signal: Stable - flat. AI confidence: MODERATE."
  },
  "crashdash": {
    "industry_intelligence": {
      "category": "BIOTECH_PHARMA",
      "name": "Biotech & Pharma",
      "icon": "\ud83e\uddec",
      "color": "#10b981",
      "crash_patterns": [
        "Clinical trial failures (Phase 1/2/3)",
        "FDA/EMA rejection or delay",
        "Safety concerns or adverse events",
        "Patent expiry or IP challenges",
        "Funding gaps (cash runway concerns)"
      ],
      "recovery_paths": [
        "Positive trial data (efficacy endpoints met)",
        "Regulatory approvals (FDA/EMA)",
        "Partnership deals (big pharma licensing)",
        "Orphan drug designation or fast track",
        "New trial initiations (pipeline expansion)"
      ],
      "active_patterns": [
        "FDA/EMA rejection or delay",
        "Safety concerns or adverse events",
        "Patent expiry or IP challenges"
      ],
      "relevant_rns_count": 1,
      "key_metrics": [
        "Clinical stage (preclinical, Phase 1/2/3, commercialized)",
        "Cash runway (months until next funding)",
        "Addressable market size (indication)",
        "Trial enrollment progress",
        "Intellectual property strength"
      ]
    },
    "panic_analysis": {
      "panic_score": 48.3,
      "signal": "MODERATE_FEAR",
      "interpretation": "\ud83d\udfe1 Cautious sentiment - assess risk/reward",
      "breakdown": {
        "price_destruction": 26.3,
        "volume_death": 14,
        "social_silence": 6,
        "news_sentiment": 2
      },
      "is_opportunity": false,
      "opportunity_reason": "\ud83d\udcca Moderate fear detected - monitor for escalation"
    },
    "fear_vs_facts": {
      "fear_points": [
        "\ud83d\udc94 Price destruction: 26/40 points"
      ],
      "facts_points": [
        "\ud83d\udcc8 Historical upside: 662% proven capacity"
      ],
      "verdict": "\u2696\ufe0f Mixed signals - Fear and facts balanced, wait for clarity"
    },
    "crashhunter_signals": [
      {
        "type": "CROWDED",
        "icon": "\u26a0\ufe0f",
        "text": "Crowded",
        "color": "#f59e0b"
      },
      {
        "type": "MODERATE_QUALITY",
        "icon": "\ud83c\udf1f",
        "text": "APEX 60",
        "color": "#3b82f6"
      }
    ],
    "catalyst_pipeline": [
      {
        "type": "rns",
        "date": "30th Jan 2026",
        "title": "Total Voting Rights",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "30th Jan 2026",
        "title": "Approval for ACCRUFeR in China expected in Q1 2026",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "21st Jan 2026",
        "title": "Q4 2025 Trading Update",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "2nd Jan 2026",
        "title": "Block listing 6 Monthly Return",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "2nd Jan 2026",
        "title": "Total Voting Rights",
        "status": "published",
        "icon": "\ud83d\udce2"
      }
    ],
    "decision_matrix": {
      "decision": "AVOID",
      "reason": "\u274c SELL/TAKE_PROFITS - timing CROWDED",
      "checklist": [
        {
          "criterion": "Panic Score",
          "value": "48/100",
          "pass": false,
          "icon": "\ud83d\udfe2"
        },
        {
          "criterion": "Timing Regime",
          "value": "CROWDED",
          "pass": false,
          "icon": "\u2705"
        },
        {
          "criterion": "APEX Quality",
          "value": "60/100",
          "pass": true,
          "icon": "\u2b50"
        },
        {
          "criterion": "Data Confidence",
          "value": "40/100",
          "pass": true,
          "icon": "\ud83c\udfaf"
        },
        {
          "criterion": "Industry Pattern",
          "value": "3 active",
          "pass": true,
          "icon": "\ud83e\uddec"
        }
      ],
      "pass_rate": "3/5"
    },
    "contrarian_panic": {
      "total_score": 47,
      "band": "\ud83d\udfe1 MODERATE COMPRESSION (Top 30% - GOOD SETUP)",
      "components": {
        "compression": {
          "score": 22,
          "max": 40,
          "signals_30d": 1,
          "signals_60d": 1,
          "signals_90d": 7,
          "signals_per_week": 0.54,
          "total_signals": 28,
          "rsi_extreme_count": 4,
          "rsi_ultra_count": 3,
          "escalation_count": 1,
          "density_score": 8,
          "rsi_score": 10,
          "escalation_score": 4,
          "description": "0.5 signals/week | 4 RSI<20 | 1 escalations | \ud83d\udcca MODERATE COMPRESSION"
        },
        "intensification": {
          "score": 5,
          "max": 20,
          "recent_types": [
            "CRASH ZONE BOTTOM",
            "CRASH ZONE BOTTOM",
            "CRASH ZONE BOTTOM"
          ],
          "escalating": false,
          "sustained": false,
          "current_intensity": 1,
          "pattern": "NORMAL CRASH LEVEL"
        },
        "volume_death": {
          "score": 5,
          "max": 15,
          "relative_volume": 2.03,
          "description": "Elevated volume - Some activity"
        },
        "pop_potential": {
          "score": 15,
          "max": 15,
          "best_historical_rally": 895.9,
          "avg_rally": 396.1,
          "signal_count": 28,
          "description": "BIG POPPER - Historical 5x+ (896%)"
        },
        "accumulation": {
          "score": 0,
          "max": 10,
          "has_accumulation": false,
          "bars_since_accum": 0,
          "description": "No accumulation"
        }
      },
      "ticker": "STX.L",
      "signal_date": "2024-07-15",
      "total_signals_history": 28
    }
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +11 (AI_Technical_Score=9.0/20)",
      "Drawdown reversion potential: +18 (Drawdown_Pct=87.5%)",
      "Volume confirmation: +10 (Relative_Volume=2.0)",
      "Pattern reliability: +5 (Rally_Count=1.0)",
      "Upside history: +16 (best_rally_pct=662%)"
    ],
    "technical_score": {
      "points": 11,
      "ai_score": 9.0,
      "reason": "AI Technical Score 9.0/20 translates to 11/25 points"
    },
    "drawdown_score": {
      "points": 18,
      "drawdown_pct": 87.55,
      "reason": "Drawdown of 87.5% gives 18/20 points"
    },
    "volume_score": {
      "points": 10,
      "rel_volume": 2.03,
      "reason": "Relative volume 2.03x gives 10 points"
    },
    "pattern_score": {
      "points": 5,
      "rally_count": 1.0,
      "reason": "1.0 historical rallies gives 5/15 points"
    },
    "upside_score": {
      "points": 16,
      "best_rally_pct": 662.5,
      "reason": "Best rally of 662% gives 16/20 points"
    },
    "penalties": {
      "total": 0,
      "items": []
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Historically strong runner - massive upside when it moves",
        "tag": "HIGH",
        "evidence": [
          "best_rally_pct=662%",
          "Rally_Count=1.0"
        ]
      },
      {
        "reason": "Proven winner - previously hit lock-in target",
        "tag": "MED",
        "evidence": [
          "lock_in_reached=True"
        ]
      }
    ],
    "reasons_to_sell": [
      {
        "reason": "Stale signal - not for active trading",
        "tag": "HIGH",
        "evidence": [
          "status=historical",
          "signal_date=2024-07-15"
        ]
      }
    ]
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Active trade",
      "action": "SELL/TAKE_PROFITS",
      "sizing": "1-3% position based on conviction",
      "risk": "Stop below recent support / invalidation level",
      "profit_taking": "Scale out into strength: 25% @ +15%, 50% @ +50%, trail runner"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "CROWDED",
    "run_multiple": 0.8,
    "current_run_pct": 532.03,
    "avg_historical_run_pct": 662.5
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "Note: this report used historical signals only \u2014 live triangulation (RNS, social, Trends) was not available. Current setup looks like CROWDED with an APEX score of 60/100. Historically there have been 1 rallies (avg. 662%); the position is now +532.0%. Practical take: this is interesting but unconfirmed \u2014 wait for an AI snapshot or clear confirmation before committing size.",
    "bull_case": [
      "Has shown very large runs historically (662% peak)"
    ],
    "bear_case": [
      "No immediate red flags, but keep stops tight"
    ],
    "timing_translation": "Late-stage rally \u2014 trim into strength and tighten risk.",
    "confidence_explained": "Confidence 40/100 \u2014 data triangulated from RNS, social and Trends."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": true,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": true
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  }
}